Dentalcorp Declares Dividend and Announces Release Date for Second Quarter 2025 Results
Dividend
The Company's Board of Directors has authorized a dividend of $0.025 per Subordinate Voting Share and Multiple Voting Share, payable on July 22, 2025 to shareholders of record at the close of business on July 3, 2025. The Company has designated this dividend as an eligible dividend within the meaning of the Income Tax Act (Canada).
Second Quarter 2025 Results Conference Call
The Company will hold a conference call to provide a business update on Friday, August 8, 2025, at 8:30 a.m. ET. A question-and-answer session will follow the business update.
About Dentalcorp
Dentalcorp is Canada's largest and one of North America's fastest growing networks of dental practices, committed to advancing the overall well-being of Canadians by delivering the best clinical outcomes and unforgettable experiences. Dentalcorp acquires leading dental practices, uniting its network in a common goal: to be Canada's most trusted healthcare network. Leveraging its industry-leading technology, know-how and scale, Dentalcorp offers professionals the unique opportunity to retain their clinical autonomy while unlocking their potential for future growth. To learn more, visit dentalcorp.ca.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Tariffs Take A Bite Out Of Deere Profit, Demand Challenges Hit Core Businesses (UPDATED)
Deere & Company (NYSE:DE) shares tumbled Thursday after the agricultural equipment giant posted mixed third-quarter results and trimmed its full-year profit forecast, highlighting persistent headwinds from declining sales, tariffs, and cautious customer demand. The heavy machinery maker reported earnings per share of $4.75, beating the consensus of $4.67. It reported a 9% decline in quarterly sales to $12.02 billion, beating the consensus of $10.31 billion. Production and precision agriculture sales decreased 16% for the quarter to $4.27 billion as a result of lower shipment volumes and unfavorable price realization. Operating profit slumped 50% to $580 million primarily due to lower shipment volumes / sales agriculture and turf sales decreased 1% to $3.03 billion due to lower shipment volumes, partially offset by favorable currency translation and price realization. Operating profit decreased 2% to $485 million due to higher tariffs, partially offset by reductions in warranty expenses and lower production costs. The decreased production costs were primarily the result of lower material costs. Construction and forestry sales decreased 5% to $3.06 billion due to unfavorable price realization. Operating profit decreased 47% to $237 million primarily due to unfavorable price realization and higher production costs caused by higher tariffs, partially offset by a favorable product mix. 'By proactively managing inventory, we've matched production to retail demand, enabling our company and dealers to respond swiftly to market shifts and customer needs,' said John May, chairman and CEO of John Deere. 'By continuing to address the high levels of used equipment in the industry, we're building a healthier market for everyone, our customers, our dealers, and our business, even in these challenging times,' May added. View more earnings on DE Deere's financial services reported a net income increasing 34% to $205 million, driven by a lower provision for credit losses. Outlook Deere narrowed its fiscal 2025 net income guidance to between $4.75 billion and $5.25 billion, compared to its previous forecast of $4.75 billion to $5.50 billion, citing that customers remain cautious amid ongoing uncertainty. 'We remain committed to delivering solutions that address our customers' current needs while also laying the groundwork for future growth. For example, the increasing utilization and proven in-field effectiveness of advanced technologies, such as See & Spray and Harvest Settings Automation, are empowering customers to improve their productivity and better navigate industry challenges,' May noted. 'The positive outcomes we're enabling reinforce our confidence in Deere's future despite near-term uncertainty.' For fiscal 2025, Deere expects production and precision agriculture sales to decline between 15% and 20%, with small agriculture and turf revenues to fall by around 10% and construction and forestry sales to decline by 10%-15%. During the earnings conference call, Deere executives reportedly said tariff costs during the third quarter were about $200 million, with the pre-tariff impact forecast for 2025 now approaching $600 million. They also noted more uncertainty in the North American agricultural market and confirmed the company will continue to run factories lean to match demand. When looking at the industry, for fiscal 2025, Deere expects the U.S. and Canada large agriculture equipment sales to decline approximately 30%, while small agriculture and turf equipment sales are projected to decrease around 10%. The company sees U.S. and Canada construction equipment sales to fall by around 10%. Price Action: DE stock is trading lower by 6.49% to $480.22 at last check Thursday. Read Next:Image via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? DEERE (DE): Free Stock Analysis Report This article Tariffs Take A Bite Out Of Deere Profit, Demand Challenges Hit Core Businesses (UPDATED) originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Business Wire
4 minutes ago
- Business Wire
LeafWorks Expands Botanical Species ID Testing to Cover the Top 75 Herbs and Fungi for Natural Products and Foods
SEBASTOPOL, Calif.--(BUSINESS WIRE)-- LeafWorks, a trailblazing botanical genomics and testing company for natural products, today announced the expansion of its DNA-based species identification services to include the most widely used herbs and fungi in natural products and foods, and their common adulterants. 'The natural products industry has long faced significant gaps in robust identification testing for challenging herbs and complex formulations. Our genetic approach fills those gaps,' - Kerin Law, Ph.D., LeafWorks Chief Scientific Officer Share In an industry where DNA testing options are lacking yet identification problems persist, this is a significant leap forward in botanical identification capabilities. The new DNA testing options give product manufacturers and sourcing managers an accurate, scalable way to confirm botanical identity—whether validating a single species or identifying multiple plant and fungal components in complex formulations. The expanded Botanical ID Testing service now offers two formats of species identification: LeafWorks® Botanical DNA ID Tests —Confirms whether a sample contains a specific species, answering the question, 'Is this the species I think it is?' LeafWorks® Adulteration DNA ID Testing —Detects common adulterants or substitutions used in natural products which can escape visual or chemistry-based detection. These are also species commonly used in many food products such as peanut, rice and wheat. These tests focus on providing reliable and robust ID testing options for the top 75 herbs and fungi in natural products, as well as common and product-specific adulterants, to solve a comprehensive scope of identification needs. Validated against a global genomic library with thousands of authenticated Botanical Reference and Certified Reference Materials—including common lookalikes, closely related sister species and adulterants—these sequencing-based tests meet 21 CFR Part 111 requirements for third-party identity verification and support full supply chain traceability. Adulteration is common in the global botanical trade, whether intentional or a byproduct of complex supply chains, such as mistaken identity. LeafWorks' DNA-based testing helps manufacturers safeguard product integrity, make informed sourcing decisions, ensure label accuracy, reduce regulatory risk, and maintain compliance. 'The natural products industry has long faced significant gaps in robust identification testing for challenging herbs and complex formulations. Our genetic approach fills those gaps,' said Kerin Law, Ph.D., LeafWorks' Chief Scientific Officer. 'DNA cannot be masked or changed. If it's present, even at trace levels, we will find it and accurately identify it using our industry-leading genomic database that took years to build with thousands of reference materials. Our clients need reliable answers, and this testing delivers exactly that.' Unlike other methods such as microscopy or macroscopy—which struggle to identify ingredients in highly processed or derived materials—or chemistry-based tests, which can miss ingredients with overlapping profiles or masked compounds, DNA analysis targets the underlying genetic code itself. As a stable, discrete material, DNA remains unaffected by cultivation conditions or the bringing together of multiple ingredients. Challenges in current identification methods are especially acute for blended products with multiple species where misidentification risk is higher — yet this is where DNA testing excels. 'DNA is built for testing identity. Development of orthogonal DNA-based identification methods that look at entire genomes and move beyond problematic barcodes or marker types will add a depth of certainty currently lacking in many species,' said LeafWorks CEO Eleanor Kuntz, Ph.D. LeafWorks' advantage goes beyond its industry-leading DNA database. By focusing on areas of the genome that are unique to each species, the company ensures the highest accuracy. Its substantial investment in a proprietary database and advanced bioinformatics pipeline enables rapid identification of these species-specific markers across thousands of samples at once, delivering unmatched precision in species identification. By integrating genomic science into routine quality control workflows, LeafWorks provides manufacturers with actionable data that supports both regulatory compliance and consumer trust. These tests help quality-assurance and quality-control teams verify ingredient identity, guide product development, assess purity, and give sourcing managers the confidence to purchase large global shipments knowing they have the correct material. 'Having reliable testing options is critical for satisfying label requirements such as 21 CFR 111, and designing a robust test takes careful genomic R&D,' added Laura Klein, Ph.D., Director of Herbal Research. 'We're proud to expand our testing to cover the top herbs and fungi used across the natural products industry, backed by rigorous methodology.' LeafWorks' Botanical ID Testing is immediately available to customers in the dietary supplements, herbal medicine, foods, cosmetics, and natural products across a diverse array of product types. For more information or to inquire about testing, visit or contact info@ About LeafWorks LeafWorks Inc. is a botanical genomics company conducting cutting-edge research and developing commercial DNA testing services for natural products. Co-founded by CEO Eleanor Kuntz, Ph.D., and CSO Kerin Law, Ph.D., the company combines scientific rigor with uncompromising ethics, specializing in DNA identification—from species ID down to trait detection—to protect and empower business operators. The company provides the necessary testing and services that help cultivators preserve their genetic IP, improve efficiency and ultimately evolve their operations. Learn more about LeafWorks Inc. at and connect on Facebook, Instagram, X and LinkedIn.
Business Wire
4 minutes ago
- Business Wire
CILA Therapeutics Awarded NCATS Grant to Advance a Transformational Platform That Significantly Enhances Inhaled Delivery of RNA-LNP Into Lung Cells
BOSTON--(BUSINESS WIRE)-- CILA Therapeutics has been awarded a competitive grant from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to advance the development of its proprietary CIL-Key™ platform — a novel, gene-agnostic delivery technology that significantly and reproducibly enhances the transfection efficiency and delivery of inhaled RNA-loaded lipid nanoparticles (RNA-LNPs) into lung epithelial cells. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine," said Safia Rizvi, CEO, CILA Therapeutics Share In preclinical studies, the CIL-Key™ platform (also referred to as CIL-0X in the grant) achieved up to a 430% increase in delivery of functionally intact RNA into human bronchial epithelial cells cultured at an air-liquid interface (ALI), demonstrating utility across multiple RNA-LNP formulations. 'This milestone provides strong validation of CILA's scientific approach and vision to deliver practical, scalable and patient-centric solutions for some of the most formidable challenges in pulmonary medicine,' said Safia Rizvi, CEO of CILA Therapeutics. CIL-Key™ is designed to enable efficient, localized intracellular delivery of RNA-based modalities while minimizing systemic exposure. The platform could offer significant advantages for companies developing inhaled RNA therapies and vaccines for a broad range of lung diseases, including Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), COPD and Pulmonary Fibrosis, as well as respiratory infections including influenza, RSV and COVID-19. Chronic pulmonary diseases affect more than 34 million people in the U.S. and more than 545 million globally. These often progressive, life-limiting conditions have a significant impact on quality of life and a high economic burden, creating an urgent demand for novel, effective and easy-to-administer treatments like those powered by CIL-Key™. About CILA Therapeutics CILA Therapeutics is a biotechnology company focused on improving lung health through transformative, scalable, accessible therapies and technologies that easily integrate into patients' daily lives. Its vision is to empower people with pulmonary diseases to breathe easily and live fully. CILA's pipeline includes first-in-class inhaled therapeutics and CIL-Key™, a proprietary platform to enhance delivery of RNA-based therapeutics and vaccines targeting a wide spectrum of pulmonary diseases. Visit CILA is actively seeking strategic partnerships to expand the platform's application across diverse RNA-based pipelines for rare and common pulmonary indications.
